{
    "root": "941d4274-57b1-4c13-a7e6-cbebfca66343",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250313",
    "ingredients": [
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "pantoprazole sodium injection indicated treatment : gastroesophageal reflux disease ( gerd ) history erosive esophagitis ( ee ) 10 days adults . pathological hypersecretory conditions including zollinger-ellison ( ze ) syndrome adults . limitations safety effectiveness pantoprazole sodium injection treatment upper gastrointestinal bleeding established adult pediatric patients . pediatric information approved pfizer inc. 's protonix\u00ae i.v . ( pantoprazole sodium ) injection . however , due pfizer inc. 's marketing exclusivity rights , product labeled information .",
        "doid_entities": [
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "gerd history ee adults : recommended 40 mg daily intravenous injection ( least 2 minutes ) intravenous infusion ( 15 minutes ) 10 days . ( 2.1 ) discontinue soon patient able receive oral treatment . switch appropriate oral medication within 10 days starting pantoprazole sodium injection . ( 2.1 ) pathological hypersecretion conditions , including ze syndrome recommended adult 80 mg every 12 hours intravenous injection ( least 2 minutes ) intravenous infusion ( 15 minutes ) . ( 2.2 ) information adjust dosing individual patient needs , full prescribing information . ( 2.2 ) switching intravenous oral formulations gastric acid inhibitors , consider pharmacodynamic action drugs ensure continuity acid suppression . ( 2.2 ) preparation instructions full prescribing information preparation instructions indication . ( 2.3 , 2.4 )",
        "doid_entities": [
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "pantoprazole sodium injection white off-white freeze-dried powder reconstitution dilution supplied follows : ndc pantoprazole sodium injection package factor 71288-600-11 40 mg pantoprazole single-dose vial 10 vials per carton storage handling store pantoprazole sodium injection 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature . ] protect light . discard unused portion . sterile , nonpyrogenic , preservative-free . container closure made natural rubber latex .",
    "adverseReactions": "pantoprazole sodium contraindicated patients known hypersensitivity including anaphylaxis formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 , 5.4 ) ( 6 ) ] . proton pump inhibitors ( ppis ) , including pantoprazole sodium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole Sodium for Injection is indicated for treatment of:\n                  \n                     gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults.\n                     pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.\n                  \n                  \n                     \n                        Limitations of Use\n                     \n                  \n                  The safety and effectiveness of Pantoprazole Sodium for Injection for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients.\n                  \n                     Pediatric use information is approved for Pfizer Inc.'s PROTONIX\u00ae I.V. (pantoprazole sodium) for Injection. However, due to Pfizer Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "GERD and a History of EE Adults: The recommended dosage is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days.\u00a0( 2.1 ) Discontinue as soon as the patient is able to receive oral treatment. Switch to an appropriate oral medication within 10 days of starting pantoprazole sodium for injection. ( 2.1 ) Pathological Hypersecretion Conditions, Including ZE Syndrome The recommended adult dosage is 80 mg every 12 hours by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes). ( 2.2 ) For information on how to adjust dosing for individual patient needs, see the full prescribing information. ( 2.2 ) When switching between intravenous to oral formulations of gastric acid inhibitors, consider the pharmacodynamic action of the drugs to ensure continuity of acid suppression. ( 2.2 ) Preparation and Administration Instructions See full prescribing information for preparation and administration instructions by indication. ( 2.3 , 2.4 )",
    "warningsAndPrecautions_original": "Pantoprazole Sodium for Injection is a white to off-white freeze-dried powder for reconstitution and dilution is supplied as follows:\n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Pantoprazole Sodium for Injection\n                           \n                           \n                              Package Factor\n                           \n                        \n                        \n                           71288-600-11\n                           40 mg of pantoprazole in a Single-Dose Vial\n                           10 vials per carton\n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store Pantoprazole Sodium for Injection at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                     Protect from light.\n                  \n                  Discard unused portion.\n                  \n                     Sterile, Nonpyrogenic, Preservative-free.\n                     \n                     The container closure is not made with natural rubber latex.",
    "adverseReactions_original": "Pantoprazole sodium is contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2, 5.4) and\u00a0Adverse Reactions (6)].\n                     Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)].",
    "drug": [
        {
            "name": "Pantoprazole Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ]
}